share_log

HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37

HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37

HC韦恩赖特公司开始对Enliven Therapeutics进行买入评级,宣布目标股价为37美元
Benzinga ·  09/09 18:27  · 评级/大行评级

HC Wainwright & Co. analyst Robert Burns initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Target of $37.

HC Wainwright & Co. 分析师罗伯特·伯恩斯开始对Enliven Therapeutics(纳斯达克股票代码:ELVN)进行报道,评级为买入,并宣布目标股价为37美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发